Boryung (003850.KS) will jointly handle sales and marketing of Atozet, a dyslipidemia treatment, with Organon Korea.
Boryung said on the 16th that it had signed a co-promotion agreement with Organon Korea for joint domestic sales and marketing of Atozet. Boryung has handled domestic distribution of the drug since Aug. 1, and the agreement expands the partnership beyond distribution into sales and marketing.
Atozet is a combination lipid-lowering therapy for patients with dyslipidemia, available in four dosage strengths that can be selected according to a patient's risk level and treatment goals. Among ezetimibe-atorvastatin combination drugs, it also offers the highest dosage, a 10-milligram and 80-milligram combination. A recent study found the drug was more effective than atorvastatin monotherapy in helping patients reach target levels of low-density lipoprotein cholesterol (LDL-C). Atozet posted sales of 109.8 billion won in South Korea alone last year.
Boryung plans to expand its position in the dyslipidemia market by drawing on the sales network it has built selling chronic disease treatments, including Kanarb, a hypertension drug it developed in-house.
"This co-promotion broadens the partnership from distribution to sales and marketing, fully combining the strengths of both companies," Boryung CEO Kim Jung-kyun said. "We will expand Boryung's influence in the dyslipidemia market on the strength of Atozet."
